No Data
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40
Express News | Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40
Enliven Therapeutics Reports Q3 Results and Clinical Progress
Express News | Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32
Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating
Express News | Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026
No Data
No Data